If You Invested in Serina Therapeutics, Inc. (SER)
Looking for the current price? See the SER quote & overviewWhat $1,000 or $10,000 in SER Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Nov 30, 2018 |
|---|---|---|---|---|
| $1,000 | $353 -65% | $62 -94% | — | $10 -99% |
| $10,000 | $3,535 -65% | $616 -94% | — | $103 -99% |
Based on real historical closing prices, dividend- and split-adjusted, through 2026-10-08. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for SER$1,000 Investment Over Time
SER vs S&P 500Year-by-Year Returns
SER annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2018 | $192.86 | $106.79 | -44.6% | -44.6% |
| 2019 | $107.14 | $65.00 | -39.3% | -66.3% |
| 2020 | $69.64 | $54.29 | -22.1% | -71.9% |
| 2021 | $56.43 | $38.93 | -31.0% | -79.8% |
| 2022 | $33.93 | $19.71 | -41.9% | -89.8% |
| 2023 | $19.96 | $13.75 | -31.1% | -92.9% |
| 2024 | $14.96 | $5.01 | -66.5% | -97.4% |
| 2025 | $5.10 | $1.9130 | -62.5% | -99.0% |
| 2026 | $2.08 | $1.99 | -4.2% | -99.0% |
About Serina Therapeutics, Inc.
Healthcare · NYSE
Serina Therapeutics, Inc. (SER) Company Overview
Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology. The company develops a pipeline of wholly owned drug product candidates for neurological diseases and other indications, with SER-252 as its main product candidate for advanced Parkinson’s disease. Serina trades on the NYSE American under the symbol SER and is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.
Serina’s business is centered on research and development of its POZ technology. The company’s reported segment relates to research and development of the POZ platform, and the available company profile describes grant revenue as the segment’s revenue source. As a clinical-stage biotechnology company, Serina’s value proposition is tied to drug candidate development, platform validation, clinical study progress, and potential partnership uses of its polymer technology.
POZ Platform Drug Optimization Technology
The POZ Platform™ is based on a synthetic, water-soluble, low-viscosity polymer called poly(2-oxazoline). Serina describes the technology as engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered through subcutaneous injection. The platform is intended to improve the integrated efficacy and safety profile of multiple modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates.
The company’s approach focuses on therapeutic agents that are typically well-understood and marketed drugs but may be limited by pharmacokinetic profiles, including toxicity, side effects, or short half-life. Serina believes POZ technology can help drugs with narrow therapeutic windows maintain more desirable and stable blood levels. The company also describes the platform as addressing limitations of polyethylene glycol and other biocompatible polymers.
SER-252 and Advanced Parkinson’s Disease
SER-252 is Serina’s lead product candidate for advanced Parkinson’s disease. Company materials describe SER-252 as designed to provide sustained apomorphine exposure. The candidate is being evaluated in a Phase 1b registrational study in patients with advanced Parkinson’s disease, and company updates have discussed safety monitoring, tolerability review, pharmacokinetic observations, and exploratory motor-function measures.
SER-252 is important to Serina because it is the company’s main named clinical program and is directly linked to the POZ Platform’s drug optimization thesis. The program gives investors and researchers a way to evaluate whether the platform can improve the delivery profile of a known therapeutic agent in a neurological disease setting.
Pipeline Scope and Platform Applications
Serina states that it is developing a pipeline of wholly owned drug product candidates for neurological diseases and other indications. Beyond small molecules, the company has described potential applications across RNA-based therapeutics and antibody-based drug conjugates. Serina has also presented work involving lipid nanoparticle drug delivery formulations built on the POZ Platform, including ionizable POZ lipids for oligonucleotide payload delivery.
The company has described additional applications of POZ technology through out-licensing, co-development, or other partnership arrangements. Company materials also identify a non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology in lipid nanoparticle drug delivery formulations. These disclosures show that Serina’s platform strategy includes both wholly owned drug candidates and external uses of its polymer technology.
What Makes Serina’s Model Distinct
Serina is a platform-focused biotechnology company built around polymer-based drug optimization rather than a single traditional small-molecule discovery program. Its materials emphasize control over drug loading, precision in release rate, subcutaneous delivery, and pharmacokinetic improvement for therapeutic agents whose limitations may include toxicity, side effects, or short half-life. That focus gives the company a clear technical theme: changing how known or well-understood therapeutic agents are delivered and released.
The company’s current public identity is also closely tied to neurological disease development. SER-252 for advanced Parkinson’s disease is the main named program, while the POZ Platform provides the broader scientific foundation for additional drug candidates and partnership applications.
Key SER Stock Research Topics
- Clinical development: SER-252 study progress, safety review, tolerability observations, and pharmacokinetic data are central company updates.
- Platform validation: Investors often focus on whether POZ technology produces the release profile and exposure pattern Serina is seeking.
- Pipeline expansion: Serina has described wholly owned drug candidates for neurological diseases and other indications.
- Partnership applications: Company materials discuss out-licensing, co-development, other partnership arrangements, and a non-exclusive Pfizer license involving POZ polymer technology for lipid nanoparticle delivery formulations.
- Regulatory filings: Serina’s filings include quarterly reports, material event reports, financing-related disclosures, governance updates, and securities registration materials.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Serina Therapeutics, Inc. investment returns
How much would $1,000 invested in Serina Therapeutics, Inc. be worth today?
If you invested $1,000 in Serina Therapeutics, Inc. (SER) 5 years ago on 2021-10-08, your investment would be worth $62 as of 2026-10-08, representing a -93.8% total return, growing at a compounded rate of -42.7% per year (CAGR).
Has Serina Therapeutics, Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare SER performance over available time periods.
What is Serina Therapeutics, Inc.'s average annual return?
The compound annual growth rate (CAGR) of SER over the past 5 years is -42.7%, growing at a compounded rate each year. Individual years vary significantly — SER's best recent year was 2026 (-4.2%) and worst was 2024 (-66.5%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
